



IMPACT REPORT

2023



IMPACT

“Since our inception, we've championed localization. Our success isn't just about funding community organizations and changemakers; it's about shifting power and amplifying the voices of our on-the-ground partners to accelerate global immunization goals.



Amy Finan

Chief Executive Officer
Sabin Vaccine Institute





2023

Contents

- 4** Letter from the Chair & CEO
- 5** Global Impact, Local Partners
- 6** Powering Research & Development
- 7** A Framework for Partnerships
- 9** Road to Phase 2: Timeline
- 11** A New Vision for Global Immunization
- 18** Impact Highlights
- 22** Project Spotlight: The Global HPV Consortium
- 24** Priority Disease Areas in 2023
- 25** Celebrating Vaccine Heroes
- 28** Sabin Staff and Board
- 29** Financials



Letter From the Chair & CEO

In 1993, three individuals planted a stake in the sand of global health and launched the Sabin Vaccine Institute with a single purpose: to advance Dr. Albert Sabin's legacy of extending immunization and its lifesaving benefits to everyone, everywhere.

Fast forward 30 years to 2023 — a year of momentous progress that would have heartened our founders. We celebrated the milestone year with several high-impact firsts and grew key initiatives, advancing new vaccines for unmet medical needs and turning existing vaccines into vaccinations.

We kicked off our first-ever Phase 2 clinical trial for a candidate vaccine last fall. Years of hard work and patience came to fruition when the first trial participant was dosed with investigational vaccine for Marburg virus disease in Uganda. Weeks later, volunteers at a second clinical site in Kenya joined the trial.

We chose to hold these human trials first in countries where both Marburg and Sudan ebolavirus (our other vaccine under development) strike the most lethal blow. With no approved vaccine yet, these diseases on average claim the lives of half of those infected, leaving a trail of devastated families and disrupted economies. The two principal investigators (PI) of Sabin's clinical trials live in these countries and have witnessed the toll exacted by these viruses — as PI Dr. Betty Mwesigwa said, "Who's best placed to test these products other than those who get these outbreaks?"

Our immunization model has always invested in local partners rather than building Sabin outposts. We work with communities on interventions to maximize vaccine access and acceptance, codesigning approaches with local stakeholders so that they are relevant and applicable to a community context and have the highest chance of adoption and success.

In September, we tapped into a long-held Sabin strength — build consensus to mobilize action — and launched the Global HPV Consortium, a movement dedicated to ending cervical cancer through vaccination, screening, and treatment. By year-end, the Consortium grew by 77%, from 22 to 39 partners.

Our local approach is a big reason why programs such as our social and behavioral research grants and the Boost community are relevant and pivotal. These programs focus on righting post-pandemic vaccination declines and reaching our most defenseless — children who have never had a single life-saving shot — by seeding local research and strengthening leadership skills for immunization professionals.

Our applied epidemiology team tackles immunization from a different and much-needed lens: generating scientific data with in-country research partners to understand disease burden and explore optimal vaccine dosing to inform vaccination policymaking.

Vaccinations have saved 154 million lives over the last 50 years. Yet, the gains accrued by immunization are under threat because access to vaccines is still inequitable and vaccine misinformation is leading to new outbreaks of vaccine-preventable diseases such as measles, a disease that had been eliminated in many countries and has now returned.

These are difficult reminders of the importance of our work, but our small, immensely dedicated staff works in tandem with our partners to meet these formidable challenges every day. Together, we will further the development of vaccines for unmet needs, explore ways to maximize the impact of existing vaccines, harness collective efforts to end diseases, and tackle both new and longstanding barriers to improving immunization uptake. Our steadfast commitment to those we serve honors the enduring legacy of Dr. Sabin and our founders as we advance global health through persistent advocacy, creative locally led solutions, and dynamic partnerships.



Regina Rabinovich, MD, MPH
Board of Trustees Chair



Amy Finan
Chief Executive Officer

Global Impact, Local Partners

Our work reflects the dedication of our collaborators on the ground.
A few of those stories are featured on these pages.



LEBANON
Leading Nurses
Through Crises
Story on [Page 16](#)



PAKISTAN
Evaluating the
Single-Dose Typhoid
Vaccine
Story on [Page 17](#)



GHANA
Advocating to Protect
Women's Health
Story on [Page 12](#)



TOGO
Adapting Strategies for
Catch-Up Vaccines
Story on [Page 14](#)



UGANDA
Testing a Marburg
Vaccine
Story on [Page 8](#)

Powering Research & Development

Sabin's small-sized R&D team took a giant step forward in 2023 by successfully kicking off a Phase 2 clinical trial for our Marburg vaccine candidate, first in Uganda, and then in Kenya. The end goal: to protect communities that are most impacted by this lethal disease and avert the next outbreak.

The first participant in the trial was vaccinated in October at our Uganda clinical partner site, Makerere University Walter Reed Project (MUWRP). Recruitment was completed about six months later with 125 healthy adults aged 18 to 70 years volunteering in the trial. Half the volunteers were enrolled at MUWRP and the other half at our other clinical partner site, Kenya Medical Research Institute (KEMRI) in Siaya, Kenya.

There are currently no approved vaccines for Marburg virus disease or for Sudan ebolavirus disease, the second vaccine candidate Sabin is working on. These viruses strike hard and are doing so with increased frequency on the African continent – on average, one of every two individuals sickened by Marburg or Sudan ebolavirus disease succumbs to it. In 2023, Marburg outbreaks in Tanzania and Equatorial Guinea caused the deaths of 18 of the 26 people confirmed infected, a nearly 70% case fatality rate.

[READ MORE](#)



“I am grateful to the many who helped us on our journey to Phase 2 clinical trials: the unstoppable perseverance and persistence of our R&D team; our funders, Biomedical Advanced Research and Development Authority (BARDA); our manufacturing partner ReiThera; our past and current colleagues at the National Institutes of Health’s (NIH) Vaccine Research Center and GSK; our clinical trial partners MUWRP and KEMRI; and the list goes on.

Amy Finan
CEO, Sabin Vaccine Institute

A Framework for Partnerships

Forging purposeful alliances across sectors to drive public health impact has long been at the heart of Sabin's work. We developed the Clinical Partnership Framework as a more intentional mechanism to engage with partners as we move our vaccines through advanced stages of development with the goals of licensure and WHO prequalification. The Framework outlines our partnership philosophy, sets baseline assumptions and expectations, and defines roles for our clinical trial efforts.

[READ MORE](#)

Pathway to Licensure

Sabin organized a Key Opinion Leaders conference in Washington D.C. on April 3, on the sidelines of the World Vaccine Congress. This was the third forum in a series convening key scientific and regulatory leaders from the private and public sectors to consider actionable steps towards filovirus vaccine licensure.

[READ MORE](#)





AMPLIFYING VOICES FROM THE FIELD

Advancing
New Vaccines &
Technologies

 Uganda

Dr. **Betty Mwesigwa** is the principal investigator at MUWRP in Uganda for Sabin's Phase 2 clinical trial for its Marburg vaccine. A physician-scientist, Dr. Mwesigwa is the deputy executive director of MUWRP and has led research for vaccines and treatments for many diseases, including HIV, Ebola Zaire, Sudan ebolavirus, and COVID-19. She believes that studies like the human trial for Marburg can help mitigate vaccine hesitancy locally and improve access to the vaccines, if approved.

[READ MORE](#)

In the scientific and clinical world, we understand very well that Marburg is as dangerous as other viral hemorrhagic fevers. In Uganda, we've had four Marburg outbreaks so far, and each of them has had fatal consequences. What makes this more concerning is that the outbreaks are sporadic. We just don't know when the next one will happen.

– **Dr. Betty Mwesigwa**
Deputy Executive Director, Makerere University Walter
Reed Project, Uganda



The Road to Phase 2

The path to developing a vaccine for any disease is complex, but even more so for outbreak-prone infections like Sudan Ebola and Marburg virus. Advancing a vaccine involves mounting parallel tracks of work such as establishing manufacturing activities to maintain the consistency of product quality; launching pre-clinical studies, non-clinical studies, and human trials; and ensuring work products will meet regulatory standards.

Below, we track Sabin's progress from our R&D program refresh in 2017 to Phase 2 clinical trials through 2023.

2017

Relaunch R&D program with renewed commitment to develop vaccines to improve human health in low- and middle-income countries

2020 - 2021

- Launch Sabin Phase 1b trial for Marburg and Sudan Ebola vaccines in the US; findings show vaccines to be safe and immunogenic in adults
- Generate critical human reagents for assays from Phase 1b trial to advance further vaccine development and support future trials
- Initiate first non-clinical study to evaluate immunogenicity and protection among non-human primates (NHP)



2019

- Acquire license from GSK for its cAd3 filovirus vaccine program, including Marburg and Sudan Ebolavirus
- Receive first contract from BARDA valued at \$128M to advance said vaccines as monovalent, single dose vaccines
- Begin building on NIH Vaccine Research Center's pre-clinical studies and Phase 1 clinical trial data



2021

Marburg

Produce bulk drug substance under Good Manufacturing Practices (GMP) with our manufacturing partner ReiThera

Sudan Ebola

Produce bulk drug substance under GMP with ReiThera

2022

CONTINUED

Marburg

- Begin fill-finish of GMP drug product at ReiThera; results in approximately 10,000 doses available for clinical trial and outbreak response use
- Conduct NHP studies to:
 - Determine efficacy with statistical significance
 - Investigate the relationship between dose and antibody responses (correlates of protection – iteration 1)

Sudan Ebola

- Begin fill-finish of GMP drug product at ReiThera; results in approximately 10,000 doses available for clinical trial and outbreak response use
- Donate approximately 1,100 vaccine doses to Uganda for outbreak response
- Conduct NHP studies to determine efficacy with statistical significance

New Contract Awarded

- Receive second BARDA contract valued at \$215M to further develop and produce Sabin's monovalent Marburg and Sudan Ebola vaccines



2023

Marburg

- Launch Phase 2 clinical trials in Uganda and Kenya
- Conduct NHP studies to explore how quickly vaccination confers protection against virus exposure
- Investigate the relationship between dose and antibody responses (correlates of protection – iteration 2)

A New Vision for Global Immunization

Sabin's Global Immunization programs deepened efforts to amplify local voices and actions on the ground, supporting countries to turn vaccines into vaccinations. We scored numerous firsts in 2023 and saw record growth for existing initiatives. A few highlights below:

- Spearheaded the successful launch of the [Global HPV Consortium](#) to reignite a lagging effort to prevent and end cervical cancer.
- Brought key issues around vaccine acceptance and demand center stage with the first in-person [Vaccination Acceptance Research Network \(VARN2023\) conference](#).
- Advanced critical efforts to prevent typhoid and other non-invasive salmonellosis at a gathering of scientists, researchers, academics, and practitioners, focusing on new breakthroughs to prevent and test for an increasingly antibiotic-resistant disease.
- Grew the Boost community by 40% over the previous year, with a sizeable number of new participants working in consequential geographies. Boost training, mentoring fellowships, and micro grants enabled immunization professionals to catch up thousands of children on routine immunizations in remote and hard-to-reach settings.
- Enrolled, immunized, and followed more than 1,450 participants in Brazil as part of Applied Epidemiology's COVID-19 fractional dosing study to optimize vaccine use.

The diversity and creativity of our Global Immunization programs has further enriched our partnerships with the World Health Organization; UNICEF; the Bill & Melinda Gates Foundation; Gavi, the Vaccine Alliance; the Wellcome Trust, CEPI, and others globally.



“The success of global health efforts hinges on our willingness to cede power, resources, and decision-making to community and country-level stakeholders. Local ingenuity and leadership can achieve audacious outcomes. I saw this firsthand in India where we eradicated polio in a nation of 1B+ people – with a strategy we developed and executed locally.”

Anuradha Gupta

President, Global Immunization,
Sabin Vaccine Institute



AMPLIFYING VOICES FROM THE FIELD

Lifting Lagging Vaccinations



Ghana

It's about perseverance, it's about working hard in life, and it's about knowing what you want to do to contribute to society when you become that someone you want to be.

– Rukaya Mumuni,
Public Health Officer, Ghana



Growing up in a small village in Ghana, where educational opportunities for girls were scarce and teen pregnancies frequent, **Rukaya Mumuni** experienced firsthand the disparities that plague marginalized communities: lack of economic opportunities, inadequate healthcare services, and social stigmatization. But a chance encounter with a nurse from her village at a clinic inspired her to pursue nursing – and advocate for improved treatment for mothers and children. Today Mumuni is a leading advocate for maternal and reproductive health, including institutionalizing screening initiatives for cervical cancer and breast cancer among hospital staff and community members, and **leading the call for HPV vaccination** in Ghana. She also inspired others – including her sister – to pursue nursing. In 2023, she was awarded a Heroine of Health by Women in Global Health in Kigali, Rwanda and named an Immunization Advocacy Champion by Nursing Now! and Sabin Vaccine Institute for her work on routine vaccination and HPV vaccination and prevention.

[READ MORE](#)



AMPLIFYING VOICES FROM THE FIELD

Moving Evidence to Action

I think very few people really know what the HPV vaccine is...the real consequences of not taking the vaccine I think are poorly understood amongst the youth.

– **Dr. Bettina Buabeng-Baidoo**,
International Working Group for Health Systems Strengthening

Dr. Buabeng-Baidoo was one of many global health experts – representing diverse fields including social and behavioral research, immunization, and vaccinology – who came together at the VARN2023 conference **to discuss community-centric solutions to spur vaccine acceptance and demand after the pandemic.**

Dr. Buabeng-Baidoo attended the event as part of the African Union Bingwa Initiative which focuses on building youth engagement throughout the continent. With a short window remaining to achieve World Health Organization goals for 2030, including reaching 90% HPV vaccination coverage of eligible girls, a key theme revolved around the challenges and opportunities of immunization campaigns. Sabin spoke to a few of the experts on the sidelines of the conference about HPV prevention and cervical cancer elimination efforts.

WATCH VIDEO





AMPLIFYING VOICES FROM THE FIELD

Leaving No
One Behind



Bamazi Karouwe Essohanam and her immunization team knew the COVID-19 pandemic had taken a toll on routine vaccination coverage at the Dalwak Medico-Social Center in Togo when the Center had been converted to COVID-19 care. **A close look at data for 2022 showed a bigger drop than expected: fewer than 50 children received routine diphtheria, tetanus, measles, or polio shots.** Essohanam joined the COVID-19 Recovery for Routine Immunization Programs Fellowship, a joint program from the Sabin Vaccine Institute and the World Health Organization. With the help of her fellowship mentor, she developed focus groups that renewed collaboration between the community and providers, and launched successful social-mobilization efforts in markets, schools, and public places. Using two strategies – a fixed site for parents to bring children to get vaccinated and mobile vaccinators – her team made progress. In just six months, 1,105 children were vaccinated in fixed posts in Dalwak, and an additional 3,482 children were vaccinated through mobile strategies. “Bringing vaccination services closer to the population reduces inequities and increases supply and demand,” she says.

[READ MORE](#)

I felt it was a great opportunity to strengthen my skills to better guide the vaccination strategies wiped out by COVID-19.

– **Bamazi Karouwe Essohanam**
Dalwak Medico-Social Center, Togo





AMPLIFYING VOICES FROM THE FIELD



Generating Evidence

“One of the things we learned was the value that health care workers and providers found in identifying key stakeholders in the community and creating collaborations in the community. Whether it’s chiefs or councils or influencers in the community, all of those places are important.”

– **Dr. Zephon Lister,**
Co-Principal Investigator, Loma Linda University, Sierra Leone

Successful community-specific interventions require significant community involvement. Sabin’s social and behavioral research grant partners worked with their communities to co-design **community-responsive strategies to address barriers to vaccine acceptance and demand**, ranging from vaccine inequities to lack of vaccine access to suboptimal delivery of vaccination services.

Eight of the partners documented their research journey as they moved through the stages of concept, implementation, evaluation, and action. Watch the first of the four-part docuseries, first shared with participants at VARN2023.

[WATCH VIDEO](#)





AMPLIFYING VOICES FROM THE FIELD

Moving Evidence to Action

Lebanon

For **Rita Akiki, MS, BSN**, working as nursing director at the Aboujaoudé Hospital in Beirut, Lebanon meant “dealing with multiple crises at the same time.” In the wake of the pandemic, an economic crisis, and health workers leaving to seek work in other countries, Akiki searched online for ways to communicate with the 130 nurses she supervises. She found the Storytelling for Change course offered through Sabin’s Boost Community and “I learned how to convince nurses to come back, to stay with us.” She became a Boost Fellow, advancing her practice with training in community activation and adaptive leadership. “I learned to identify my strengths, my weaknesses, and to plan proactively,” she says. **The skills of storytelling, planning, and relationship-building have become part of Akiki’s leadership practice**, and she rounds more deliberately, checking in with patients *and* her staff. “We have become a more positive environment, working as a unit, so everybody is helping each other. All this came from learning and the communication.”

[READ MORE](#)

Usually in Lebanon they like doctors, not nurses, but due to the COVID pandemic, what was beautiful was that the population now understands the importance of nurses.

– Rita Akiki

Nursing Director, Aboujaoudé Hospital, Lebanon





AMPLIFYING VOICES FROM THE FIELD

Generating
Evidence



Pakistan

The longevity of immune response following a single dose of typhoid conjugate vaccine needs to be analyzed further, especially in younger children and in countries with a high force of infection.

– Dr. Farah Naz Qamar

Associate Professor and Consultant Pediatric Infectious Disease,
The Aga Khan University, Pakistan

A four-year study of children aged less than ten years in Pakistan showed that a single dose of the typhoid conjugate vaccine (TCV) provides protection for at least four years. Though Pakistan was the first country in the world to introduce TCV into its routine immunization program for children in 2019, the study highlighted the need for continued surveillance and monitoring to assess population impact of routine TCV vaccination and the age-specific immune response to vaccination.

[READ MORE](#)



Impact Highlights:

Exploring Vaccine Acceptance and Demand

233 grant applications received for social and behavioral research; **7 partners selected**; **4 new countries** reached

Docuseries supported to highlight insights from 8 partners researching vaccination uptake in their local contexts

403 new members joined the Vaccination Acceptance Research Network (VARN), growing it by **49%**

880 journalists from 93 countries **participated** in 28 Sabin co-hosted events to improve media's understanding of immunization





Impact Highlights:

Generating Evidence



Phase 2 Marburg vaccine clinical trial started, enrolling 125 participants in Uganda and Kenya

1,451 vaccinated participants studied in COVID-19 fractional dose trial in Brazil

903 participants enrolled in COVID-19 fractional dose trial in Pakistan

Typhoid surveillance study begun in Cote d'Ivoire and Afghanistan to inform investments in typhoid prevention and control



Impact Highlights:

Strengthening Immunization Capacity

18 Boost program modules offered on a wide range of **immunization-critical topics** to build adaptive leadership and community activation skills; advance local problem-solving; and create space for peer-to-peer engagement and learnings

3,470 immunization professionals from 118 countries **enrolled, connected, and engaged** through 57 learning sessions





Impact Highlights:

Convening for Change

The 14th International Rotavirus Symposium

- 275 attendees from 35 countries
- 55 presentations

The Global HPV Consortium

- 125 participants and representatives from 10 countries
- 75 action-planning session participants

VARN2023 | First In-Person Gathering

- 231 delegates from 47 countries
- 128 speakers

13th International Conference on Typhoid & Other Invasive Salmonellosis

- 360 researchers from 44 countries
- 196 posters and oral presentations

Social and Behavioral Research Grants (SBRG) Partner Coalition Meeting

- 50 grant partners from 4 cohorts
- 7 research teams (4th cohort) presented



Project Spotlight:

The Global HPV Consortium



To inspire global efforts to prevent human papillomavirus (HPV) infection and eliminate cervical cancer – the first cancer ever targeted for eradication – **Sabin Vaccine Institute and 22 founding partners launched the Global HPV Consortium in 2023 in Kuala Lumpur, Malaysia.**

Among those kicking off the Consortium: former Prime Minister of New Zealand H.E. Helen Clark, Director-General of the World Trade Organization Dr. Ngozi Okojo-Iweala, plus country leaders, policy makers, implementers, researchers, youth advocates, women champions, non-profits, and industry representatives.

Designed to cut across traditional silos, **the Consortium, led by Sabin as Secretariat, quickly grew over 2023 to include organizations working on vaccination, cancer control, non-communicable diseases, HIV, reproductive and adolescent health, gender equity, and women empowerment.** By the end of the year there were 39 partners, with 33% country-based partners.

The Consortium supports the World Health Organization's integrated 90-70-90

strategy of 90% of women vaccinated, 70% screened, and 90% treated by 2030.

Cervical cancer affects more than 600,000 women each year. It kills approximately 350,000 women annually and without action, cervical cancer is projected to increase almost 50% by 2040.



“

We know there have been more than 1.5 million women who have died from cervical cancer over the last five years. What a stunning number for a disease we know we can prevent. Strategies are great. Action has to follow. That's why we are creating this Global HPV Consortium. We have to turn that around, and fast.



H.E. Helen Clark

Former Prime Minister of
New Zealand

Dr. Ngozi Okonjo-Iweala


Director-General
World Trade Organization



From an economic perspective, it's really important to eliminate cervical cancer. There is a breathtaking statistic: if women were to have the same opportunities as men to contribute globally, we would add another \$28 trillion to the global economy. Imagine if we save these women's lives.

“

Priority Disease Areas in 2023



COVID-19: We continued to apply lessons from the pandemic to improve how these vaccines are developed and delivered, with a focus on advancing countries' ability to access, develop, and distribute vaccines effectively.



HPV: We are working across multiple fronts to prevent HPV and eliminate cervical cancer. We have coalesced the Global HPV Consortium, a public-private partnership to mobilize action across three pillars — vaccination, screening, and treatment — and reduce incidence and deaths from cervical cancer. HPV is responsible for an estimated 95% of all cervical cancers. More than 340,000 women, many in their prime, succumb to the disease each year.



INFLUENZA: Our work focuses on accelerating the development of next-generation vaccines that offer broader protection for influenza to better prepare for and prevent the next pandemic.



MARBURG VIRUS: Sabin is advancing a vaccine for the deadly Marburg virus disease that is now in Phase 2 clinical trials. Marburg virus disease is fatal in up to 88% of cases. No licensed vaccine for the disease exists. In recent years, Marburg virus disease outbreaks have grown in frequency and ferocity. Sabin is an active member of WHO's MARVAC, a group of experts from industry, government, non-profit organizations, and academia dedicated to the rapid development of Marburg vaccines.



SUDAN EBOLAVIRUS: Sabin's candidate vaccine for Sudan ebolavirus is in Phase 2 clinical trials. The virus is lethal, killing, on average, one out of every two people infected. No licensed vaccine for the disease exists.



TYPHOID: We are collaborating with local researchers in high-risk communities to gather and analyze data on disease spread and the impact of new vaccines that are rolled out in countries.

We **FOCUS** on vaccines for **DISEASES** that place a heavier burden on the **HEALTH** and **LIFE EXPECTANCY** of individuals and communities in low- and middle-income countries.

AWARDS

Celebrating Vaccine Heroes

2023 Gold Medal and Rising Star Awards

On June 5, Sabin honored **Dr. Thomas (Tom) Monath** with the 30th Albert B. Sabin Gold Medal and **Dr. Sangwe Clovis Nchinjoh** with the 2023 Rising Star award.

The occasion was significant for two additional reasons: It marked three decades of the Gold Medal and was the first in-person ceremony since the COVID-19 pandemic began. The Gold Medal is Sabin's highest scientific honor and has been awarded since 1994 to distinguished members of the global health community for making exceptional contributions to vaccinology or a complementary field.

WATCH VIDEO




2023 Albert B. Sabin Gold Medal Recipient

Thomas Monath, MD

Dr. Monath was selected for his enduring commitment to advancing vaccine research for diseases found largely in low- and middle-income countries. He has made pivotal contributions to the development of vaccines for Ebola Zaire, dengue, Japanese encephalitis and West Nile virus, to name a few. He has served in the public and private sector, developing a novel platform for vaccine development and winning regulatory approval for four human vaccines, including a second-generation smallpox vaccine.

[READ MORE](#)



I learned early in my career that vaccine access to underserved populations was so important — and that the availability of good preventive vaccines is only the first step in the control of infectious diseases.

2023 Sabin Rising Star Recipient

Sangwe Nchinjoh, MD, MPH

Sabin's Rising Star was established in 2020 to recognize and highlight the work of emerging vaccine leaders like Dr. Nchinjoh. A public health physician and researcher based in Cameroon, Dr. Nchinjoh used ground-breaking approaches to identify and successfully immunize more than 8,500 zero-dose children, a remarkable achievement that aligns with Sabin's goal of ensuring that every child has access to life-saving vaccinations.

[READ MORE](#)



“Accepting this award reminds me of the importance of resilience, planning, and dedication in achieving our goals. It also underscores the significance of never losing sight of the individuals and the communities that we serve.”

Staff and Board

(AS OF 2023)

EXECUTIVE STAFF

Amy Finan
Chief Executive Officer

Kiju deLeon, CPA
Chief Financial Officer

Anuradha Gupta
President, Global Immunization



BOARD OF TRUSTEES

Regina Rabinovich, MD, MPH
Chair
Executive Committee Chair
Governance Committee Chair

**Richard A. Adegbola, PhD, FIMLS,
FRCPath, FRCP (Hon), FAS**

Norman Baylor, PhD

Yacine Djibo, MBA

Amy Finan
Chief Executive Officer

Elizabeth Fox, PhD

Wendy Commins Holman

Axel Hoos, MD, PhD

Jeffrey P. Libson, JD

Saad Omer, MBBS, MPH, PhD

**David Salisbury, CB, FMedSci,
FRCP, FRCPath, FFPH**
Global Immunization Chair

Jacqueline Shea, PhD

JoAnn Suzich, PhD
R&D Committee Chair

Peter L. Thoren
Vice Chair
Treasurer
Finance & Audit Committee Chair



MEMBERS

Financials

How We Used Our Funds in 2023



- **88%**
\$37,286,000
on programs
- **12%**
\$4,962,000
on organizational
management &
administration
- **0.7%**
\$278,000
on resource
development &
fundraising to support
future growth

Program Expenditures in 2023



- **73%**
\$27,130,000
on Vaccine R&D
- **27%**
\$10,156,000
on Global Immunization

How You Can Help Us

As a health promotion leader, Lillyan Mutua has worked on vaccine acceptance for the past decade. She knows she needs new ideas and mentoring to make any progress in her work for the Kenya Ministry of Health. Mutua joined Sabin's Boost Community and has taken 14 different professional development courses — all free of charge — and also received a Fellowship in the first Sabin/World Health Organization's COVID-19 Recovery for Routine Immunization Programs.

Your donations can help partners who work to improve immunization's reach around the globe.

WAYS TO GIVE

It is time that we review, reinvent, create new innovations for doing things. Stop looking at the issues that are impeding us from having successful vaccine delivery. Look from where we have been, where we are, and where we want to go.

— Lillyan Mutua, Head of Health Promotion,
Kenya Ministry of Health, Nairobi





S **SABIN**
VACCINE INSTITUTE

2000 Pennsylvania Ave, NW, Suite 7000
Washington, DC 20006
+1 202 842 5025
info@sabin.org
www.sabin.org

